论文部分内容阅读
预防和治疗器官移植的排异反应,目前着重于:1.供体和受体的组织配型要适合;2.器官移植后连续应用免疫抑制剂。20年来免疫抑制剂基本上是硫唑嘌呤和类固醇的联合应用。近来肾移植的技术已有很大进展而移植肾的存活率却没有大的变化,故迫切祈望有新型的免疫抑制剂的供应。最近瑞士发明的环孢素A(Cyclosprin A),是一种真菌提取物,分子量1202,具有11个氨基酸的蝶形环多肽,供口服,90％从肝脏排泄。经动物和人体器官移植的实践证明,环
Prevention and treatment of rejection of organ transplantation, the current focus on: 1. donor and recipient tissue matching to be fit; 2. organ transplant continuous application of immunosuppressive agents. For 20 years, immunosuppressants have basically been the combination of azathioprine and steroids. Recently, the technology of kidney transplantation has made great progress and there is no big change in the survival rate of kidney transplant. Therefore, there is an urgent need for a new type of immunosuppressant supply. Cyclosprin A, recently invented in Switzerland, is a fungal extract with a molecular weight of 1202 and an 11-amino acid butterfly loop polypeptide for oral administration and excretion of 90% from the liver. The practice of organ and human organ transplantation proved that ring